Accuray faces a challenging fundamental outlook characterized by a 7.4% year-over-year revenue decline in 2026Q3 and structural margin compression that has pushed gross margins down to 24.1%. The company's inability to achieve consistent operating leverage, co...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 19, 2026 | -$0.02+33.3% vs -$0.03 | $101M-4.2% vs $105M |
Q2 2026 May 6, 2026 | -$0.09-80.0% vs -$0.05 | $105M-6.3% vs $112M |
Q1 2026 Feb 4, 2026 | -$0.11-2.2% vs -$0.11 | $102M+1.4% vs $101M |
Q4 2025 Nov 5, 2025 | -$0.18-1700.0% vs -$0.01 | $94M-23.6% vs $123M |
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive CapabilitiesPR Newsw
MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today announced that they had entered into a definitive agreement providing for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy.
BlackRock Inc. bought a new position in Accuray Incorporated (NASDAQ: ARAY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,266,185 shares of the medical equipment provider's stock, valued at approximately $842,000. BlackRock Inc. owned approximately 2.75% of Accuray
Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
Benchmark ARAY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Accuray Incorporated (ARAY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.23 | $27.36M | -14.84 | 2.68% | -0.35% | -2.52% | — | |
| $402.09 | $142.05B | 51.09 | 20.51% | 28.45% | 17.71% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $103.73 | $180.68B | 27.88 | 5.67% | 13.91% | 12.09% | — | |
| $44.92 | $66.77B | 23.15 | 19.87% | 17.47% | 14.76% | — | |
| $90.77 | $116.54B | 24.34 | 8.43% | 13.93% | 10.51% | — |
Accuray Incorporated (ARAY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Accuray Incorporated (ARAY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 19, 2026·SEC
Aug 6, 2026·SEC
Jul 29, 2026·SEC
Get notified when ARAY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Accuray Incorporated (ARAY) stock FAQ — growth, dividends, profitability & financials explained
Accuray Incorporated (ARAY) reported $401.9M in revenue for fiscal year 2025. This represents a 1696% increase from $22.4M in 2005.
Accuray Incorporated (ARAY) grew revenue by 2.7% over the past year. Growth has been modest.
Accuray Incorporated (ARAY) reported a net loss of $49.2M for fiscal year 2025.
Accuray Incorporated (ARAY) has a return on equity (ROE) of -2.5%. Negative ROE indicates the company is unprofitable.
Accuray Incorporated (ARAY) had negative free cash flow of $15.8M in fiscal year 2025, likely due to heavy capital investments.
